Abstract:Scavenger receptor class B type I (SR-BI) is a major receptor for high-density lipoproteins (HDL) in the liver. Overexpression of SR-BI attenuated experimental atherosclerosis in murine models, concomitant with a reduction in plasma HDL-cholesterol levels. Probucol is known to be a potent hypolipidemic drug to regress xanthoma formation and carotid atherosclerosis in conjunction with a marked reduction in HDL-cholesterol levels. However, the mechanism by which probucol affects atherosclerosis is not completely understood, and the effect of probucol on the expression of SR-BI was controversial. The aim of this study was to know the effect of probucol on HDL metabolism and SR-BI expression in the liver.Sixteen rabbits fed with high cholesterol diet for 8 weeks were randomly divided into two groups: (1) high cholesterol group (n = 8): maintained high cholesterol diet for 6 weeks; (2) probucol group (n = 8): the same cholesterol diet plus 1% probucol for 6 weeks. Control group (n = 8) was fed with normal diet for 14 weeks. The classical in situ two steps perfusion of the liver with collagenase IV was used to isolate the parenchymal hepatocytes. The selective uptake of HDL by hepatocytes was performed using the double radiolabelled HDL. Immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) were used to evaluate SR-BI expression in the liver.Compared with control group, rabbits fed with high cholesterol diet showed higher levels of serum total cholesterol (TC), low-density lipoprotein (LDL) cholesterol and HDL-C, all of which were significantly reduced by probucol treatment. The selective uptake of HDL CEs in probucol group (249.68 +/- 60.13 ng/mg cell protein) was about two folds higher as compared with the control group (122.47 +/- 54.06 ng/mg cell protein, P < 0.01) and high cholesterol group (104.92 +/- 47.91 ng/mg cell protein, P < 0.01), but it could not be reproduced in vitro. The expression of SR-BI were significantly decreased in the high cholesterol group (0.48 +/- 0.06) as compared with control group (0.65 +/- 0.06, P < 0.01). Probucol increased SR-BI expression (0.68 +/- 0.06, P < 0.01) as compared with high cholesterol group. The expression of SR-BI was positively associated with the selective CEs uptake (r = 0.47, P = 0.032).Probucol up-regulates SR-BI expression and enhance the uptake of HDL CEs by hepatocytes, which may help us to understand the anti-atherogenic properties and the HDL-C-lowering effect of probucol.

Abstract 288: Atheroprotective Effect of Probucol is Related to Its Heme Oxygenase 1 Activation and Subsequent Suppression of Oxidized Low-Density Lipoprotein--Induced Dendritic Cell Maturation

Abstract P298: Probucol Inhibits Oxidized Low-Density Lipoprotein--Induced Immune Maturation of Dendritic Cells Via Heme Oxygenase 1

Probucol Protects Against Atherosclerosis Through Lipid-lowering and Suppressing Immune Maturation of CD11c+ Dendritic Cells in STZ-induced Diabetic LDLR−/− Mice

New insights into mechanism for the effect of probucol in anti-atherosclerosis: Possible role of inhibitor on immune maturation of dendritic cells

Probucol Protects Endothelial Progenitor Cells Against Oxidized Low-Density Lipoprotein via Suppression of Reactive Oxygen Species Formation In Vivo.

Probucol Protects Against Atherosclerosis Through Induction of Heme Oxygenase-1

Probucol alleviates atherosclerosis and improves high density lipoprotein function

Probucol Inhibits Atherosclerosis by Regulating ABCA1, SR-B I, ABCG5 and ABCG8 Expression and Anti-inflammatory Effects in Hypercholesterolemic Rabbits

Probucol Inhibits Expression of CD36 Induced by Oxidized Low-density Lipoprotein in Macrophages

Microrna-181A Represses Ox-Ldl-stimulated Inflammatory Response in Dendritic Cell by Targeting C-Fos

Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.

Effect of Probucol on Adhesion of Human Monocytic Line THP-1 Induced by Oxidiz Ed Low Density Lipoprotein

Effect of the Anti-Oxidant Probucol on Soluble Thrombomodulin (stm) in Hypercholesterolemic Rabbits

Probucol reduces myeloperoxidase expression in peripheral blood monocytes from patients with acute coronary syndrome

Probucol inhibits expression of fractalkine induced by oxidized low-density lipoprotein in human umbilical vascular endothelial cells

Probucol Up-Regulates Paraoxonase 1 Expression in Hepatocytes of Hypercholesterolemic Rabbits

Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice

Probucol Decreases Asymmetrical Dimethylarginine Level by Alternation of Protein Arginine Methyltransferase I and Dimethylarginine Dimethylaminohydrolase Activity

Protective Effect of Probucol on Oxldl-Induced Inhibition of HUVEC Cell Proliferation

Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.

Probucol mitigates high-fat diet-induced cognitive and social impairments by regulating brain redox and insulin resistance